Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

William Claytor

Nurse Practitioner Jacksonville, FL Nurse Practitioner

NPI 1023424587 CMS profile 10741740

1660 Prudential Dr Ste 400, Jacksonville, FL 32207

Open in the dashboard

General payments

$10,568

578 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, William Claytor of Jacksonville, FL is reported in the CMS Open Payments database as having received $10,568 across 578 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,024 96
2024 General $2,416 123
2023 General $2,232 129
2022 General $2,398 135
2021 General $1,499 95

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • William Claytor
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to William Claytor were reported at $2,024. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year William Claytor Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $1,499 $135 $40–$426 $132
2022 $2,398 $152 $48–$470 $149
2023 $2,232 $166 $54–$529 $160
2024 $2,416 $173 $55–$556 $164
2025 $2,024 $174 $55–$557 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Novo Nordisk Inc $1,241 76 payments
  2. AbbVie, Inc. $1,157 64 payments
  3. AstraZeneca Pharmaceuticals LP $1,155 56 payments
  4. Lilly USA, LLC $1,075 66 payments
  5. Pfizer Inc. $932 58 payments
  6. Amgen Inc. $630 36 payments
  7. Boehringer Ingelheim Pharmaceuticals, Inc. $601 29 payments
  8. GlaxoSmithKline, LLC. $465 27 payments
  9. Bayer HealthCare Pharmaceuticals Inc. $361 23 payments
  10. Abbott Laboratories $313 15 payments
  11. Other $2,637 128 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $10,568 578 payments
Products named General payments · program years 2021–2025
  1. FARXIGA $678 26 payments
  2. UBRELVY $650 36 payments
  3. Ozempic $602 39 payments
  4. RYBELSUS $581 38 payments
  5. NURTEC ODT $552 33 payments
  6. AIRSUPRA $514 18 payments
  7. MOUNJARO $507 34 payments
  8. Repatha $449 28 payments
  9. QULIPTA $444 23 payments
  10. ELIQUIS $437 26 payments
  11. Other $8,635 476 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 59 drugs

Part D claims

1,618

Median for Nurse Practitioner: 389

Drug cost

$156,481

Median for Nurse Practitioner: $21,885

Branded share of claims

16.3%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Mounjaro Tirzepatide Brand 48 $45,909
Ozempic Semaglutide Brand 27 $27,701
Jardiance Empagliflozin Brand 30 $25,295
Eliquis Apixaban Brand 20 $21,206
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 18 $12,914
Farxiga Dapagliflozin Propanediol Brand 11 $8,547
Celecoxib Generic 15 $1,458
Gabapentin Generic 51 $1,078
Metoprolol Succinate Generic 47 $907
Atorvastatin Calcium Generic 106 $873

The 10 drugs with the highest cost, of 59 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 31 billing codes

Paid by Medicare

$62,726

Of which drugs: $9,785

Medicare patients

433

Average age 75

Services billed

1,063

253 women, 180 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 58%
Ischemic heart disease 39%
Diabetes 32%
Chronic kidney disease 28%
COPD 22%
Depression 22%
Heart failure 20%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Pcv20 vaccine im 90677 Office 15 15 $4,062
Vaccine for influenza for injection into muscle 90662 Office 25 25 $2,046

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 33 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
UBRELVY
  • AbbVie, Inc. $208
$208 — —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $201
$201 — —
VOQUEZNA
  • Phathom Pharmaceuticals, Inc. $191
$191 — —
JARDIANCE
  • Lilly USA, LLC $116
  • Boehringer Ingelheim Pharmaceuticals, Inc. $57
$173 30 —
FARXIGA
  • AstraZeneca Pharmaceuticals LP $165
$165 11 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 33 with Patron

Records

578 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record